Table 3 Treatment characteristics
Characteristics | SRS | HFSRT | All patients |
|---|---|---|---|
Days from diagnosis to RT | 34 (15–99) | 35 (23–61) | 34 (15–99) |
Device used for RT | |||
 Novalis (BrainLAB) | 40 (52) | 12 (16) | 52 (69) |
 Cyberknife (Accuray) | 20 (26) | 5 (6) | 23 (31) |
GTVres | 4.6 (0.3–9.6) | 15.3 (2.4–31.3) | 5.37 (0.3–31.3) |
PTVres | 8.4 (1.8–21) | 22.6 (4.9–45.5) | 10.6 (1.8–45.5) |
PTVres ≥ 15 | 6 (8) | 14 (18) | 20 (26) |
PTVres < 15 | 54 (70) | 3 (4) | 57 (74) |
Cavity min. Dose | 17.2 (6.3–19.7) | 36.9 (19.3–40) | 17.5 (6.3–40) |
Cavity mean dose | 18.3 (16.6–24.5) | 39.9 (24–45.7) | 19.2 (16.6–45.7) |
Cavity max. Dose | 19.1 (17–20.4) | 40.4 (24.2–50) | 20.4 (17–50) |
Isodose line in % | 80 (70–83) | 80 | 80 (70–83) |
Margin used for cavity | |||
 0 | 3 (4) | 0 (0) | 3 (4) |
 0.5–1.5 | 40 (52) | 12 (16) | 52 (68) |
 1.8–2.5 | 17 (22) | 5 (6) | 22 (28) |
Median margin for cavity | 1 (0–2.5) | 1 (1–2) | 1 (0–2.5) |
Conformality index | 1.14 (1–1.68) | 1.12 (1–1.67) | 1.13 (1–1.68) |
Patients with in situ BMs | 7 (9) | 3 (4) | 10 (13) |
 GTVin situ | 0.46 (0.19–1.67) | 0.85 (0.06–2.18) | 0.47 (0.06–2.18) |
 PTVin situ | 0.48 (0.42–1.67) | 1.05 (0.38–3.48) | 0.51 (0.38–3.48) |
 Min. dosein situ | 19.8 (18.6–21.5) | 19.8 (19.6–38.3) | 19.9 (18.6–38.3) |
 Mean dosein situ | 22.7 (22–24.1) | 21.4 (21.1–43.6) | 22.6 (21.1–43.6) |
 Max. dosein situ | 25 (22.5–25.3) | 22.2 (21.8–47.5) | 25 (21.8–47.5) |